440 related articles for article (PubMed ID: 11520776)
21. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
[TBL] [Abstract][Full Text] [Related]
22. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
23. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
Iwakiri R; Ohta M; Mikoshiba M; Tsutsumi H; Kumakawa T; Mori M
Int J Hematol; 2002 Jan; 75(1):45-50. PubMed ID: 11843290
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
26. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
27. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
28. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR
Blood; 2000 Dec; 96(13):4075-83. PubMed ID: 11110676
[TBL] [Abstract][Full Text] [Related]
29. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
Woods WG; Kobrinsky N; Buckley JD; Lee JW; Sanders J; Neudorf S; Gold S; Barnard DR; DeSwarte J; Dusenbery K; Kalousek D; Arthur DC; Lange BJ
Blood; 1996 Jun; 87(12):4979-89. PubMed ID: 8652810
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Delaunay J; Vey N; Leblanc T; Fenaux P; Rigal-Huguet F; Witz F; Lamy T; Auvrignon A; Blaise D; Pigneux A; Mugneret F; Bastard C; Dastugue N; Van den Akker J; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Dombret H; ; ; ; ;
Blood; 2003 Jul; 102(2):462-9. PubMed ID: 12649129
[TBL] [Abstract][Full Text] [Related]
31. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
32. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
33. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Rao A; Hills RK; Stiller C; Gibson BE; de Graaf SS; Hann IM; O'Marcaigh A; Wheatley K; Webb DK
Br J Haematol; 2006 Mar; 132(5):576-83. PubMed ID: 16445830
[TBL] [Abstract][Full Text] [Related]
34. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
Godwin JE; Kopecky KJ; Head DR; Willman CL; Leith CP; Hynes HE; Balcerzak SP; Appelbaum FR
Blood; 1998 May; 91(10):3607-15. PubMed ID: 9572995
[TBL] [Abstract][Full Text] [Related]
35. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Tavernier E; Le QH; Elhamri M; Thomas X
Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
[TBL] [Abstract][Full Text] [Related]
36. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
[TBL] [Abstract][Full Text] [Related]
37. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
38. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Burnett AK; Hills RK; Milligan DW; Goldstone AH; Prentice AG; McMullin MF; Duncombe A; Gibson B; Wheatley K
J Clin Oncol; 2010 Feb; 28(4):586-95. PubMed ID: 20038732
[TBL] [Abstract][Full Text] [Related]
39. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
[TBL] [Abstract][Full Text] [Related]
40. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]